Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 124 от 154

Активно (без набиране) Фаза 2

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

Melanoma Merkel Cell Carcinoma, Unspecified Renal Cell Carcinoma Non Small Cell Lung Cancer

The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.

Начало: 09.12.2021 Край: 01.07.2025 Възраст: от 18 г. Диагностика

Australia, Belgium, Netherlands +3 ImaginAb, Inc. NCT05013099

Активно (без набиране) Фаза 3

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Gastric Neoplasms Gastroesophageal Adenocarcinoma Esophageal Adenocarcinoma

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).

Начало: 02.12.2021 Край: 31.07.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +29 Jazz Pharmaceuticals NCT05152147

Активно (без набиране) Фаза 1

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Gastrointestinal Stromal Tumors

This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged to be refractory to imatinib, estimate the recommended dose, evaluate safety and pharmacokinetics, and observe the antitumor effect. Expansion part consists of 3 arms. In Arm A, the efficacy and safety will be evaluated, which of the combination of pimitespib and imatinib in patients with GIST who have failed imatinib at doses below the MTD determined in Dose Escalation Part. In Arm B, the efficacy and safety of pimitespib monotherapy will be evaluated and the therapeutic effect of imatinib administration after pimitespib will be evaluated in an exploratory manner. In Arm C, the efficacy and safety of sunitinib monotherapy will be evaluated as reference data.

Начало: 01.12.2021 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, China, Japan +2 Taiho Pharmaceutical Co., Ltd. NCT05245968

Активно (без набиране) Фаза 3

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Atherosclerotic Cardiovascular Disease

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Начало: 23.11.2021 Край: 13.10.2027 Възраст: 40–100 г. Лечение

Argentina, Australia, Belgium +43 Novartis Pharmaceuticals NCT05030428

Активно (без набиране) Фаза 3

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 Plexiform Neurofibroma (PN)

A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.

Начало: 19.11.2021 Край: 15.02.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +10 AstraZeneca NCT04924608

Активно (без набиране)

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

Atopic Dermatitis

Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on the use patterns and outcomes with upadacitinib in a real-world setting. Therefore, the purpose of this observational study is to help inform real-world usage patterns regarding the safety and effectiveness and duration of response of upadacitinib in adolescent and adult AD participants \>=12 years old in the real-world setting. Upadacitinib is an approved drug being developed for the treatment of AD. Around 975 adolescent and adult participants who are prescribed upadacitinib for the treatment of AD in routine clinical practice will be enrolled worldwide. Participants will receive oral upadacitinib as prescribed by their physician. Data from these participants will be collected for approximately 2 years. There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.

Начало: 17.11.2021 Край: 01.10.2026 Възраст: от 12 г.

Argentina, Australia, Canada +12 AbbVie NCT05081557

Активно (без набиране) Фаза 3

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).

Начало: 17.11.2021 Край: 01.01.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +15 Gilead Sciences NCT05089734

Активно (без набиране) Фаза 3

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia

Начало: 17.11.2021 Край: 01.10.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Bulgaria +20 argenx NCT04812925

Активно (без набиране)

Feasibility Study of the Vessel Restoration System (VRS): ACTIVATE II

PAD - Peripheral Arterial Disease

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA): ACTIVATE II

Начало: 15.11.2021 Край: 15.11.2027 Възраст: от 18 г. Лечение

Australia Alucent Biomedical NCT05454995

Активно (без набиране)

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) After Sub-optimal Percutaneous Transluminal Angioplasty (PTA) or Atherectomy: REACTIVATE I

PAD - Peripheral Arterial Disease

Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) after Sub-optimal percutaneous transluminal angioplasty (PTA) or Atherectomy: REACTIVATE I

Начало: 15.11.2021 Край: 15.11.2026 Възраст: от 18 г. Лечение

Australia Alucent Biomedical NCT05455021

Активно (без набиране) Фаза 2

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Amyotrophic Lateral Sclerosis

This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.

Начало: 13.11.2021 Край: 01.08.2026 Възраст: 30–80 г. Лечение

Australia Clene Nanomedicine NCT05299658

Активно (без набиране) Фаза 2

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS). This is an extension of other miransertib studies (MK-7075-002 \[NCT03094832\] or ArQule CU/EAP \[NCT03317366\]), and may also enroll participants who are approved for MK-7075-002 but have not yet started miransertib therapy.

Начало: 02.11.2021 Край: 07.02.2030 Възраст: 2–120 г. Лечение

Australia, Brazil, Italy +2 Merck Sharp & Dohme LLC NCT04980872

Активно (без набиране) Фаза 1

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Advanced Solid Tumor NSCLC

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Начало: 29.10.2021 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia, Poland, Spain +1 Cullinan Therapeutics Inc. NCT05117476

Активно (без набиране) Фаза 3

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Papillary Renal Cell Carcinoma

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).

Начало: 28.10.2021 Край: 30.10.2025 Възраст: 18–130 г. Лечение

Argentina, Australia, Brazil +22 AstraZeneca NCT05043090

Активно (без набиране) Фаза 3

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Relapsed or Refractory Follicular Lymphoma

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.

Начало: 27.10.2021 Край: 31.12.2029 Възраст: от 18 г. Лечение

Australia, Brazil, China +12 Hoffmann-La Roche NCT04712097

Активно (без набиране) Фаза 3

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Amyloid Cardiomyopathy, Transthyretin-Related

Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Начало: 27.10.2021 Край: 15.05.2028 Възраст: 18–90 г. Лечение

Australia, Belgium, Brazil +14 Eidos Therapeutics, a BridgeBio company NCT04988386

Активно (без набиране) Фаза 3

Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis

Shock, Septic

This multicentre, randomised controlled trial will enrol 1000 patients presenting with septic shock to the emergency department (ED) of participating hospitals in Australia and New Zealand. Participants will receive haemodynamic resuscitation with either a restricted fluids and early vasopressor regimen or a larger initial IV fluid volume with later introduction of vasopressors if required. Clinical care including the type of resuscitation fluid and vasopressor agent, will otherwise be in accordance with accepted standard care and according to clinician discretion. The study intervention will be delivered for at least 6 hours and up to 24 hours post-randomisation. Participants will be followed for up to 12 months and outcomes analysed on an intention-to-treat basis.

Начало: 26.10.2021 Край: 03.11.2026 Възраст: от 18 г. Лечение

Australia, Ireland, New Zealand Australian and New Zealand Intensive Care Research Cent NCT04569942

Активно (без набиране) Фаза 2

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

HER2 Positive Metastatic Breast Cancer

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd

Начало: 26.10.2021 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia, South Korea, United States Ambrx, Inc. NCT04829604

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.

Начало: 26.10.2021 Край: 14.03.2028 Възраст: 18–75 г. Лечение

Argentina, Brazil, Czechia +11 Hoffmann-La Roche NCT04963296

Активно (без набиране) Фаза 3

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Gastro-enteropancreatic Neuroendocrine Tumor

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.

Начало: 22.10.2021 Край: 01.07.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +9 Camurus AB NCT05050942

1 … 122 123 124 125 126 … 154